MOH — authorised 31 December 2012
- Marketing authorisation holder: SALIX PHARMS
- Status: likely_approved
MOH authorised Mytesi on 31 December 2012
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. MOH authorised it on 31 December 2012.
SALIX PHARMS holds the Israeli marketing authorisation.